In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. by Jenkins, WS et al.
1868  Jenkins WS, et al. Heart 2019;105:1868–1875. doi:10.1136/heartjnl-2019-315103
Original research
In vivo alpha- V beta-3 integrin expression in human 
aortic atherosclerosis
William s Jenkins   ,1 alex T Vesey,1 anna Vickers,1 anoushka neale,1 
catriona Moles,1 Martin connell,2 nikhil Vilas Joshi,1 christophe lucatelli,2 
alison M Fletcher,2 James c spratt,1 saeed Mirsadraee,2 edwin Jr van Beek,2 
James hF rudd   ,3 David e newby,1 Marc r Dweck1 
Aortic and vascular disease
To cite: Jenkins Ws, Vesey aT, 
Vickers a, et al. Heart 
2019;105:1868–1875.
 ► additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2019- 315103).
1British heart Foundation 
centre for cardiovascular 
science, University of edinburgh, 
edinburgh, UK
2clinical research imaging 
centre, University of edinburgh, 
edinburgh, UK
3Division of cardiovascular 
Medicine, University of 
cambridge, cambridge, UK
Correspondence to
Dr William s Jenkins, centre 
for cardiovascular science, 
University of edinburgh, 
edinburgh eh16 4TJ, UK;  
 williamjenkins@ doctors. net. uk
received 24 March 2019
revised 15 July 2019
accepted 17 July 2019
Published Online First 
17 august 2019
 ► http:// dx. doi. org/ 10. 1136/ 
heartjnl- 2019- 315487
© author(s) (or their 
employer(s)) 2019. re- use 
permitted under cc BY. 
Published by BMJ.
AbsTrACT
Objectives intraplaque angiogenesis and inflammation 
are key promoters of atherosclerosis and are mediated 
by the alpha- V beta-3 (αvβ3) integrin pathway. We 
investigated the applicability of the αvβ3- integrin 
receptor- selective positron emission tomography (PeT) 
radiotracer 18F- fluciclatide in assessing human aortic 
atherosclerosis.
Methods Vascular 18F- fluciclatide binding 
was evaluated using ex vivo analysis of carotid 
endarterectomy samples with autoradiography and 
immunohistochemistry, and in vivo kinetic modelling 
following radiotracer administration. Forty- six subjects 
with a spectrum of atherosclerotic disease categorised 
as stable (n=27) or unstable (n=19; recent myocardial 
infarction) underwent PeT and cT imaging of the 
thorax after administration of 229 (iQr 217–237) MBq 
18F- fluciclatide. Thoracic aortic 18F- fluciclatide uptake 
was quantified on fused PeT- cT images and corrected 
for blood- pool activity using the maximum tissue- to- 
background ratio (TBrmax). aortic atherosclerotic burden 
was quantified by cT wall thickness, plaque volume and 
calcium scoring.
results 18F- Fluciclatide uptake co- localised with 
regions of increased αvβ3 integrin expression, and 
markers of inflammation and angiogenesis. 18F- 
Fluciclatide vascular uptake was confirmed in vivo using 
kinetic modelling, and on static imaging correlated with 
measures of aortic atherosclerotic burden: wall thickness 
(r=0.57, p=0.001), total plaque volume (r=0.56, 
p=0.001) and aortic cT calcium score (r=0.37, p=0.01). 
Patients with recent myocardial infarction had greater 
aortic 18F- fluciclatide uptake than those with stable 
disease (TBrmax 1.29 vs 1.21, p=0.02).
Conclusions in vivo expression of αvβ3 integrin in 
human aortic atheroma is associated with plaque burden 
and is increased in patients with recent myocardial 
infarction. Quantification of αvβ3 integrin expression 
with 18F- fluciclatide PeT has potential to assess plaque 
vulnerability and disease activity in atherosclerosis.
InTrOduCTIOn
Atherosclerotic cardiovascular disease is the most 
common cause of death worldwide, and elucidating 
the mechanisms underlying the propagation and 
rupture of atherosclerotic plaques remains a key 
public health goal.1 Although our understanding 
of the pathogenesis underlying atherosclerosis has 
progressed over the last two decades, accurate 
prediction of clinical events remains elusive. There 
is therefore considerable interest in non- invasive 
imaging techniques that go beyond the detection 
of luminal stenoses and instead focus on measuring 
disease activity within the vasculature.2 3
Combined positron emission tomography (PET) 
and CT is a non- invasive hybrid imaging tech-
nique that integrates targeted functional molecular 
imaging with high- detail anatomical definition. 
This technique has been used to quantify vascular 
inflammation and calcification activity with success 
in both carotid and coronary atherosclerosis.4–7 
Recently, intraplaque angiogenesis and neovascular-
isation has emerged as a key factor in the develop-
ment, progression and instability of atherosclerotic 
plaques.8 The integrin alpha- V beta-3 (αvβ3) cell 
surface receptor is upregulated on endothelial cells 
in states of angiogenesis and is also observed on 
macrophages at sites of increased vascular inflam-
mation, another key contributor to plaque insta-
bility. This receptor helps coordinate interaction 
between cellular components and the extracellular 
matrix, and contains a distinctive RGD- amino acid 
sequence (the arginine- glycine- aspartate motif) in 
the cell- ligand interaction site. On this basis, several 
PET tracers targeting the RGD sequence have been 
developed for monitoring angiogenesis in malignant 
tumours.9 10 These tracers have also shown promise 
in monitoring atherosclerotic activity in preclinical 
models8 11–14 and in a recent small study of patients 
with carotid atheroma.7
18F- Fluciclatide is a novel RGD- based PET 
radiotracer with high affinity for the αvβ3 integrin 
receptor.10 15 16 We hypothesised that 18F- fluci-
clatide may act as an imaging marker of athero-
sclerotic disease activity in vivo, informing about 
both inflammation and angiogenesis. In this study, 
we sought to characterise the cellular and imaging 
characteristics of 18F- fluciclatide uptake in human 
atherosclerosis using a clinical cohort of patients 
with both stable and unstable clinical disease.
MeThOds
study populations
In total we studied 50 patients. Four patients were 
recruited who had sustained a recent stroke and 
were undergoing carotid endarterectomy. In these 
patients, excised carotid plaques were examined 
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using histology and 18F- fluciclatide autoradiography. For in vivo 
imaging, 46 patients were recruited from the Royal Infirmary of 
Edinburgh between July 2013 and December 2014. This cohort 
comprised 19 unstable patients with a recent acute ST- segment 
elevation myocardial infarction (MI) (14±7 days after MI) 
(NCT01813045),17 and 27 stable patients with either stable 
angina (n=6) or asymptomatic atherosclerotic disease (n=21; 
12 had calcific aortic valve disease) (NCT01837160). Exclusion 
criteria were age <40 years, women of childbearing potential, 
severe renal failure (estimated glomerular filtration rate <30 mL/
min) or hepatic failure (Child- Pugh grade B or C), atrial fibrilla-
tion, known contrast allergy, inability to undergo scanning and 
inability to provide informed consent. All 46 subjects underwent 
18F- fluciclatide PET imaging alongside clinical assessment that 
included evaluation of cardiovascular risk and high- sensitivity 
C- reactive protein (hs- CRP) measurement (Biocheck, Foster 
City, California, USA).
This study was conducted in accordance with the Decla-
ration of Helsinki and with written informed consent of each 
participant.
radiosynthesis of 18F-fluciclatide
18F- Fluciclatide was manufactured at the Clinical Research 
Imaging Centre on an automated module (FASTlab synthe-
siser; GE Healthcare) by coupling an amino- oxy- functionalised 
peptide precursor (AH111695) with 4–18F- fluorobenzaldehyde 
at pH 3.5 to form 18F- fluciclatide.17 A full description of this 
synthesis has been published previously.16
histological validation
Carotid endarterectomy specimens (online supplementary 
data) were fresh frozen and sectioned in cryosection medium. 
Both atheromatous and non- atheromatous segments were 
fixed, stained with H&E and examined by immunohistochem-
istry for smooth muscle actin, CD31, CD68 and αvβ3 integrin 
receptor expression before digital image capture (Axioscan.Z1, 
Zeiss, UK). Image analysis was performed on ImageJ32 soft-
ware (National Institutes of Health, Bethesda, Maryland, USA). 
Staining was expressed as a percentage of the total plaque area 
and with an object size set threshold applied at 20×10 pixels, to 
limit counting to cell- sized objects. The density of cell staining 
in the endarterectomy tissue was expressed as cells per mm2.18
Autoradiography was performed to identify the precise local-
isation of 18F- fluciclatide binding in atherosclerotic tissue. 
Carotid sections were bathed in a solution of 18F- fluciclatide 
(1 kBq/mL) for 60 min and rinsed with phosphate buffer solu-
tion. To rule out non- specific radiotracer uptake, an un- labelled 
highly concentrated solution of fluciclatide was added to bind 
competitively with the αvβ3 integrin receptors. 18F- Fluciclatide 
binding was imaged using a FujiFilm FLA-5100 Fluorescent 
Image Analyser (Raytek Scientific, Sheffield, UK).
Clinical 18F-fluciclatide PeT imaging
All patients in the imaging cohort underwent PET- CT imaging 
of the thorax with a hybrid scanner (Biograph mCT, Siemens 
Medical Systems, Erlangen, Germany) at the Clinical Research 
Imaging Centre, University of Edinburgh. Subjects were admin-
istered a target dose of 230 MBq 18F- fluciclatide. An attenua-
tion correction CT scan (non- enhanced 120 kV and 50 mA, 3 
mm slices) was performed prior to PET acquisition. To define 
tracer pharmacodynamics and the optimum timing of scanning, 
dynamic PET imaging of the thorax was performed in the initial 
20 patients in three- dimensional (3- D) mode using a single bed 
position for 70 min. For the remainder of the study subjects, 
static imaging was performed at the optimal time point (found to 
be 40 min postinjection) using a single 30 min bed position in list 
mode with electrocardiographic gating. Immediately after PET 
acquisition, thoracic CT angiography was performed (online 
supplementary data).
PeT image reconstruction and analysis
Kinetic analysis was performed on the dynamic PET studies 
to investigate the pharmacodynamics of 18F- fluciclatide 
uptake within atheroma. The methodology is described in 
detail in the online supplementary data. In all patients, static 
electrocardiogram- gated PET images were reconstructed in dias-
tole (40–70 min postinjection, 50%–75% of the R- R interval, 
Ultra- HD, 2 iterations, 21 subsets, zoom ×2, 200 pixels). Images 
were analysed by experienced observers blinded to the demo-
graphic data (WJ, AV) using an OsiriX workstation (OsiriX 
V.6.0 64- bit; OsiriX Imaging Software, Geneva, Switzerland). 
PET images were fused with the attenuation correction CT, 
and regions of interest drawn around the thoracic aorta on 
serial axial slices just beyond the discernible adventitial border. 
Aortic uptake was assessed in three regions: the ascending 
thoracic aorta (from the level of mid- right pulmonary artery up 
to the last slice where the aorta maintained its circular cross- 
sectional appearance), the descending thoracic aorta (the region 
extending from the tip of the diaphragm up to the last circular 
slice) and the aortic arch (the region of the aorta connecting 
the ascending and descending aorta). Within these regions, mean 
and maximum tracer activities were measured using standard 
uptake values (SUV; the decay corrected tissue concentration of 
the tracer divided by the injected dose per body weight, kBq/
mL) and corrected for mean radiotracer blood pool activity to 
provide a mean of the TBRmax (mean TBRmax).
5 19 20 The blood 
pool radiotracer activity was quantified in the superior vena cava 
(SVC), measured in the axial plane on 4–5 sequential 5 mm axial 
slices above the level of the junction of the left innominate vein. 
In a substudy of 10 randomly selected subjects, images were 
assessed independently by two experienced observers and the 
interobserver reproducibility of 18F- fluciclatide SUV and TBR 
measurements assessed.
CT image reconstruction and analysis
The aortic CT calcium score was calculated for the aorta as 
a whole and for its different regions using axial slices on the 
attenuation correction CT dataset (OsiriX V.6.0 64- bit; OsiriX 
Imaging Software) and expressed in arbitrary units (AU).21 In 
those patients whose descending aorta was visualised within 
contrast CT datasets (n=33), further measures of aortic athero-
sclerotic plaque burden were made on dedicated plaque analysis 
software (Vital Images, Minnetonka, Minnesota, USA). Using 
the sagittal plane, the entire portion of the descending thoracic 
aorta within the field of contrast CT acquisition was delineated 
and the luminal blood pool removed using semi- automated 
thresholding. The mean aortic wall thickness was recorded and 
corrected for the vessel diameter providing the indexed wall 
thickness. Additionally, the aortic wall volume was recorded and 
corrected for total vessel volume to provide an indexed plaque 
volume.
statistical analysis
Continuous data were tested for normality visually and with 
the D’Agostino- Pearson omnibus test. Continuous data were 
presented as median (IQR) and compared using Pearson’s or 
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Figure 1 18F- Fluciclatide uptake in carotid atheroma. (A) 
Autoradiography image of segments of ruptured carotid plaque (left) 
and proximal healthy segments (right). Greater 18F- fluciclatide binding 
is visible within plaque rupture segments. Binding within the tissue 
segments (demarcated, black) was successfully blocked by the addition 
of a more concentrated un- labelled solution of fluciclatide (B). Areas 
showing the highest fluciclatide binding (demarcated, blue) exhibited a 
high degree of alpha- V beta-3 integrin expression (C and D, arrow) that 
also featured cellular staining for vascular endothelial cells (CD31, E and 
F, arrow) and inflammatory cells (CD68, G and H, arrow). Scale bar=1 
mm in C, E, G and 75 µm in D, F, H.
Spearman’s correlation or Wilcoxon signed- rank test as appro-
priate. Aortic calcium score and hs- CRP were log- transformed to 
base 10 to achieve normality prior to statistical analysis. Interob-
server reproducibility was calculated by Bland Altman method 
and presented as mean bias ±2 SD, and intraclass correlation 
coefficients (ICC).22 Mann- Whitney U test was used to assess 
continuous variables across groups of a categorical variable. A 
matched stable atheroma group was created through censoring 
of patients with stable atheroma and high levels of aortic calcifi-
cation by researchers blinded to the PET data. Statistical analysis 
was performed with GraphPad Prism V.6 (GraphPad Software, 
California, USA). A two- sided p<0.05 was taken as statistically 
significant.
resulTs
Plaque autoradiography and histology
Autoradiography of carotid plaque demonstrated focal 18F- flu-
ciclatide binding in regions of advanced atherosclerosis that was 
effectively blocked by un- labelled fluciclatide (figure 1A, B). On 
adjacent tissue sections processed for histology, these regions 
of ex vivo 18F- fluciclatide uptake co- localised with areas of 
intense cellular staining of αvβ3 integrin (45.2 (29.1–66.9) cells/
mm2, % area 4.2 (3.2–5.7)), microvascular endothelial cells at 
sites of angiogenesis and positive remodelling (CD31+; 23.0 
(6.5–63.0) cells/mm2, % area 2.5 (2.2–4.9)), and inflammatory 
macrophages deeper adjacent to the necrotic core (CD68+; 32.0 
(21.0–49.8) cells/mm2, % area 3.7 (2.4–5.6), figure 1C–H). By 
comparison regions of carotid endarterectomy specimen without 
visible atheroma did not demonstrate 18F- fluciclatide uptake, 
and had much lower levels of αvβ3 integrin receptor expression 
(4.5 (4.3–5.2) cells/mm2, % area 0.6 (0.5–2.0), both p=0.05 
compared with areas with increased 18F- fluciclatide expression), 
as well as staining for both angiogenic endothelial cells (CD31+; 
2.1 (1.8–2.4) cells/mm2, % area 0.9 (0.6–1.2), both p=0.05) and 
inflammatory macrophages (CD68+; 4.3 (2.8–4.4) cells/mm2, 
% area 0.6 (0.5–1.2), both p=0.03).
In vivo imaging cohort
A total of 46 subjects underwent PET imaging with CT angiog-
raphy (age 66±10 years, 74% male; table 1) following injection 
of 229 (IQR 217–237) mBq 18F- fluciclatide. Of the 46 subjects 
recruited, 19 had suffered a recent MI (unstable cohort), and 
27 had imaging evidence of aortic atherosclerosis on CT but 
no recent cardiovascular events (stable cohort: 6 with stable 
angina and 21 with subclinical disease who were asymptomatic 
with no prior cardiovascular events). Interestingly, those in the 
stable cohort had greater aortic calcification than patients in 
the unstable group (AU (IQR); 326 (11–1114) vs 19 (0–483), 
p<0.01), reflecting their greater age (years (IQR); 69 (66–74) 
vs 60 (51–70), p=0.01). The groups were well matched for 
gender (p=0.97) and body mass index (p=0.39), and were 
both characterised by high prevalence of atherosclerotic risk 
factors, with more smokers in the unstable group (p<0.001) and 
more patients with hypertension in the stable group (p=0.02). 
No adverse events were reported following administration of 
18F- fluciclatide and the average total radiation dose per partic-
ipant was 15 mSv.
dynamic analysis of aortic 18F-fluciclatide uptake
On kinetic analysis (n=20), activity within aortic atheroma 
increased gradually, reaching a plateau at 40–70 min. Injected 
18F- fluciclatide activity has a biexponential blood pool clearance 
with a half- life of about 10 min consisting of a fast redistribution 
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Table 1 Patient characteristics
All
(n=46)
stable atherosclerosis
(n=27)
unstable atherosclerosis
(n=19) P value*
Age (years) 67 (60–74) 69 (66–74) 60 (51–70) 0.01
Male sex 34 (74) 20 (74) 14 (74) 0.97
BMI (kg/m2) 28 (25–31) 28 (24–30) 27 (25–32) 0.39
Systolic BP (mm Hg) 140 (124–160) 149 (134–167) 125 (114–139) <0.001
18F- Fluciclatide dose (MBq) 229 (217–237) 228 (217–236) 229 (215–240) 0.69
Cardiovascular history
  Angiographically documented CAD 26 (57) 7 (26) 19 (100) <0.001
  Prev MI 24 (52) 5 (19) 19 (100) <0.001
  Prev PCI 20 (43) 2 (7) 18 (95) <0.001
  Prev CVD 4 (11) 4 (14) 0 (0) 0.08
Risk factors
  Current smoker 9 (20) 1 (4) 8 (42) 0.001
  Diabetes mellitus 6 (13) 4 (14) 2 (10) 0.58
  Prior hypertension 23 (50) 18 (67) 6 (32) 0.02
  Prior hypercholesterolaemia 25 (54) 12 (44) 12 (63) 0.21
  hs- CRP (mg/L) 3.5 (1.4–7.8) 2.7 (1.4–5.8) 5.6 (2.0–11.7) 0.08
Medications
  Aspirin 28 (61) 10 (37) 19 (100) <0.001
  Clopidogrel 19 (41) 4 (14) 19 (100) <0.001
  Statin 31 (67) 13 (48) 19 (100) <0.001
  β-Blocker 27 (59) 8 (30) 19 (100) <0.001
  ACEi/ARB 31 (67) 10 (37) 18 (95) <0.001
  Calcium channel blocker 7 (15) 6 (22) 1 (5) 0.11
Categorical data are displayed as n (%).
Continuous data are displayed as median (IQR).
*P values are quoted for comparisons between matched stable and unstable groups.
ACEi, ACE- inhibitor; ARB, angiotensin receptor blocker; AS, aortic stenosis; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CVD, cerebrovascular disease; 
IHD, ischaemic heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; hs- CRP, high- sensitivity C reactive protein.
Figure 2 Kinetic analysis of aortic 18F- fluciclatide uptake. Sagittal views of the thorax following kinetic analysis in two participants with (patient 1: 
A–E) and without (patient 2: F–H) aortic arch 18F- fluciclatide uptake. CT images confirm presence (A) or absence (F) of aortic arch calcification as a 
marker of established atheroma. Patlak slope (Ki) parametric images (B and G) identify focal uptake within the aortic arch in the region of atheroma 
(red arrow) localising to the vessel wall on the fused Patlak and CT images (C and H). Patlak modelling (D) confirms irreversible integrin binding 
within the region of aortic arch calcification (red arrow). Time activity curves (TAC) within the same region (E) show a persistently high blood pool 
fraction, but uptake within atheroma that exceeds the blood pool fraction beyond 40 min (dashed line).
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Table 2 Imaging results
All
(n=46)
stable atherosclerosis
(n=27)
Matched stable 
atherosclerosis (n=19)*
unstable atherosclerosis
(n=19) P value†
18F- Fluciclatide PET uptake
  SVC (SUVmean) 2.73 (2.35–3.05) 2.66 (2.21–2.96) 2.47 (2.07–2.78) 2.88 (2.61–3.26) 0.01
  Whole aorta (mean SUVmax) 3.65 (3.04–4.01) 3.43 (2.95–3.81) 3.04 (2.86–3.61) 3.87 (3.46–4.12) 0.002
  Whole aorta (mean TBRmax) 1.31 (1.20–1.39) 1.29 (1.20–1.38) 1.25 (1.19–1.36) 1.32 (1.17–1.42) 0.32
  Ascending aorta (mean TBRmax) 1.32 (1.23–1.37) 1.27 (1.23–1.36) 1.24 (1.20–1.34) 1.33 (1.18–1.39) 0.10
  Aortic Arch (mean TBRmax) 1.28 (1.16–1.40) 1.27 (1.14–1.37) 1.21 (1.13–1.33) 1.29 (1.25–1.44) 0.02
  Descending aorta (mean TBRmax) 1.31 (1.19–1.42) 1.30 (1.23–1.41) 1.26 (1.17–1.41) 1.32 (1.12–1.45) 0.97
CT calcium score
  Whole aorta (AU) 95 (0–852) 326 (11–1114) 36 (0–469) 19 (0–483) 0.85
  Ascending aorta (AU) 0 (0–11) 0 (0–46) 0 (0–0) 0 (0–0) 0.15
  Aortic arch (AU) 29 (0–352) 102 (0–586) 13 (0–469) 0 (0–263) 0.76
  Descending aorta (AU) 7.5 (0–78) 0 (0–123) 0 (0–123) 8 (0–71) 0.43
CTA plaque analysis (descending aorta)
  Mean wall thickness (% vessel diameter) 9.1 (6.5–12.8) 8.0 (6.3–10.0) 8.1 (6.3–9.8) 12.8 (8.6–18.4) 0.009
  Plaque burden (% total volume) 8.3 (6.1–11.4) 7.4 (6.0–9.1) 7.5 (5.9–8.9) 11.4 (7.9–15.6) 0.008
Data are presented as median (IQR).
CTA, computed tomography angiography.
* Stable group subjects paired to equivalent calcium score in unstable group.
† P values are quoted for comparisons between matched stable and unstable groups.
AU, arbitrary units; CTA, Computed Tomography Angiography; PET, positron emission tomography; SUV, standard uptake value; SVC, superior vena cava; TBR, tissue- to- 
background ratio.
Table 3 PET uptake and baseline characteristics
Total aortic 18F- fluciclatide uptake
All patients stable cohort unstable cohort
Continuous variables
  CT calcium score (log10 AU) r=0.37 (0.08–0.60), p=0.01 r=0.62 (0.43–0.81), p<0.001 r=0.20 (−0.28–0.60), p=0.41
  Mean wall thickness (% vessel diameter)* r=0.57 (0.28–0.76), p<0.001 r=0.18 (−0.26–0.56), p=0.43 r=0.69 (0.15–0.91), p=0.02
  Plaque volume (% total volume)* r=0.56 (0.26–0.75), p<0.001 r=0.16 (−0.28–0.55), p=0.47 r=0.68 (0.13–0.90), p=0.02
  Log10 hs- CRP (mg/L) r=0.18 (−0.14–0.46), p=0.28 r=0.32 (−0.07–0.62), p=0.10 r=−0.24 (−0.63–0.24), p=0.06
Categorical variables
  Hypertension (mean TBRmax) 1.33 (1.19–1.39) vs
1.29 (1.20–1.40), p=0.91
1.27 (1.21–1.38) vs
1.33 (1.19–1.38), p=0.90
  
  Established ischaemic heart disease (mean TBRmax) 1.34 (1.22–1.42) vs
1.25 (1.19–1.35), p=0.15
1.37 (1.37–1.42) vs
1.25 (1.19–1.35), p=0.04
  
  Hypercholesterolaemia (mean TBRmax) 1.34 (1.21–1.42) vs
1.27 (1.19–1.34), p=0.17
1.36 (1.29–1.41) vs
1.25 (1.19–1.30), p=0.01
  
  Diabetes mellitus (mean TBRmax) 1.37 (0.32–0.45) vs
1.29 (1.19–1.38), p=0.09
1.37 (1.28–1.58) vs
1.29 (1.19–1.37), p=0.15
  
  Current smokers (mean TBRmax) 1.32 (1.24–1.49) vs
1.29 (1.19–1.39), p=0.54
N too small   
*18F- Fluciclatide uptake assessed in the descending aorta only, to correspond with CT analysis.
AU, arbitrary units; PET, positron emission tomography; TBR, tissue- to- background ratio; hs- CRP, high sensitivity C- reactive protein.
component with a slower clearance component, causing rela-
tively high residual blood pool activity during PET acquisition 
(40–70 min postinjection, SVC SUVmean 2.73 (IQR 2.35–3.05); 
figure 2). Consequently, while 18F- fluciclatide uptake in aortic 
atheroma was measurable above background, TBRmax were rela-
tively low (TBRmax range 1.08–1.68; tables 2 and 3, figures 2 
and 3). In the 3- D Patlak slope (Ki) parametric images, six data-
sets (30%) were uninterpretable due to patient movement. In 
the remaining studies, increased aortic 18F- fluciclatide uptake 
was observed in half of subjects. Patlak modelling demonstrated 
a discernible linear phase suggesting irreversible ligand- receptor 
binding over the selected acquisition time and a greater Ki slope 
in these subjects compared with patients with no aortic uptake 
(figure 2). Subjects with uptake present on Patlak analysis (n=7) 
also appeared to have higher 18F- fluciclatide uptake on stan-
dard analysis (TBRmax 1.32±0.05 vs 1.19±0.03, p=0.08) and 
greater aortic calcification (aortic calcium score 704 (28–1788) 
vs 0 (0–119) AU, p=0.06) than those without visible uptake, 
although this did not reach statistical significance.
Aortic 18F-fluciclatide uptake reproducibility studies
Using static PET images, quantification of 18F- fluciclatide 
blood- pool activity demonstrated excellent interobserver repro-
ducibility, with no fixed or proportional bias (SUVmean mean 
difference; −0.11 (−0.36–0.15)) and a good ICC coefficient 
(0.95, online supplementary table S2). Quantification of aortic 
18F- fluciclatide uptake using the established mean TBRmax 
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Figure 3 18F- Fluciclatide aortic uptake. Patient 3: modified coronal 
view of the aortic arch showing radiotracer uptake at the inner 
curvature of the aortic arch related to a region of aortic calcification. 
This activity is demonstrated on axial sections of the aorta (i and ii). 
Red lines indicate the adventitial borders of the aortic arch used for 
quantification of PET uptake. Patient 4: sagittal view of the thorax 
displaying focal 18F- fluciclatide uptake within a region of vascular 
calcification in the aortic arch.
Figure 4 18F- Fluciclatide uptake, atheroma burden and clinical 
stability. Graphs displaying the relationship between aortic 18F- 
fluciclatide uptake and aortic plaque burden, assessed using both the 
plaque volume (A) and calcium score (B). Moreover, 18F- fluciclatide 
uptake was greater in patients with unstable (recent myocardial 
infarction) vs stable (no recent cardiovascular events) atherosclerotic 
disease (C). TBR, tissue- to- background ratio.
approach5 20 also displayed no fixed or proportional bias (mean 
difference; 0.08 (−0.01–0.16)) with good ICC (0.92) (online 
supplementary table S1).
Aortic 18F-fluciclatide uptake and atheroma burden
Our study cohort comprised patients with a wide spectrum of 
aortic atherosclerotic burden (aortic calcium score range 0–6857 
AU). On static PET images, aortic 18F- fluciclatide uptake demon-
strated a moderate relationship with disease burden in the aorta 
using both CT calcium scoring (r=0.37 (0.08–0.60), p=0.01) 
and the indexed plaque volume (r=0.56 (0.26–0.75); p<0.001) 
(table 3, figures 3 and 4). A good correlation was also observed 
with the relative vessel wall thickness (expressed as a percentage 
of vessel diameter, r=0.57 (0.28–0.76); p<0.001). There was 
no correlation between aortic 18F- fluciclatide uptake and the 
inflammatory marker CRP (log10 hs- CRP r=0.18, p=0.28).
Aortic 18F-fluciclatide uptake in stable and unstable patients
To establish whether 18F- fluciclatide uptake may be a marker 
of unstable atherosclerotic activity, we compared aortic uptake 
in patients who had sustained a recent MI with those in our 
stable cohort. Given the association demonstrated between 
18F- fluciclatide activity and plaque burden, we matched 
patients in the two groups according to CT calcium score (online 
supplementary table S2). We demonstrated increased 18F- fluci-
clatide aortic arch uptake in patients with recent MI compared 
with those in the stable cohort (TBRmax; 1.29 (IQR 1.25–1.44) 
vs 1.20 (1.13–1.33, p=0.02)) despite equivalent aortic calcium 
scores (table 2, figure 4). Moreover, in patients with recent MI, a 
stronger correlation was observed between aortic plaque burden 
and 18F- fluciclatide uptake than in the patient population as a 
whole (aortic wall thickness r=0.68, p=0.02). When aortic SUV 
measurement were assessed, these were consistently increased in 
the unstable groups compared with the stable groups across all 
regions of the aorta, even before attempts were made to match 
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these groups by calcium score (p<0.05 for all aortic regions, 
table 2 and online supplementary table S3).
Aortic 18F-fluciclatide and cardiovascular risk factors
Among patients in the stable cohort, aortic 18F- fluciclatide 
uptake correlated with a number of risk factors (table 3). 
18F- Fluciclatide activity was higher in patients with hypercho-
lesterolaemia compared with those without (TBRmax; 1.36 (IQR 
1.29–1.41) vs 1.25 (IQR 1.19–1.30), p=0.01) and those with a 
diagnosis of coronary heart disease (TBRmax; 1.37 (IQR 1.37–
1.42) vs 1.25 (IQR 1.19–1.35), p=0.04) . An apparent observed 
trend was also seen in patients with diabetes (TBRmax; 1.37 
(1.28–1.58) vs 1.29 (1.19–1.37), p=0.15), although this did 
not meet statistical significance. Again, a strong correlation was 
observed between 18F- fluciclatide uptake and the CT calcium 
score (r=0.62, p<0.001) in this subgroup.
dIsCussIOn
We present the largest multimodality imaging study to date eval-
uating the application of an RGD- based αvβ3 integrin receptor 
radiotracer in the assessment of human atheroma. We have demon-
strated that ex vivo 18F- fluciclatide binding co- localises to sites of 
αvβ3 integrin receptor expression in excised carotid plaques, and 
this was associated with regions of both angiogenesis and inflam-
mation. We have further demonstrated in vivo that 18F- fluciclatide 
uptake increased with progressive atherosclerotic plaque burden 
and is higher in patients with unstable versus stable atheroscle-
rotic disease. These data would suggest that 18F- fluciclatide holds 
promise as a non- invasive marker of disease activity in athero-
sclerosis, informing us about two key characteristics of high- risk 
atheroma: inflammation and angiogenesis. RGD- based tracers 
may therefore aid our pathophysiological understanding of this 
important condition and help identify patients at increased risk of 
adverse cardiovascular events.
Plaque inflammation and angiogenesis are two key pathological 
processes associated with atheroma progression, plaque rupture 
and clinical events. Macrophages drive expansion of the necrotic 
core and secrete matrix metalloproteinases that weaken the fibrous 
cap, predisposing it to rupture. Angiogenesis is believed to occur 
in response to hypoxic conditions within the necrotic core and is 
associated with high- risk plaque characteristics.3 In addition, these 
new vessels are prone to leakage and rupture resulting in plaque 
haemorrhage that itself results in a pro- inflammatory response, 
plaque destabilisation and clinical events. A non- invasive imaging 
technique that can inform about the activity of these two adverse 
pathological processes might therefore be useful in identifying 
patients with active high- risk atheroma. Indeed, it is hoped that 
non- invasive markers of systemic atherosclerotic disease activity 
may identify the vulnerable patient and provide incremental risk 
prediction to an assessment of radiographic coronary or carotid 
disease burden alone.2 23 We have here demonstrated that 18F- flu-
ciclatide PET- CT is an emerging and promising approach to 
achieve these aims.
Our autoradiographic data showed focal 18F- fluciclatide 
binding within carotid atheroma that localised histologically 
to αvβ3 integrin expression with no evidence of non- specific 
binding. Regions of 18F- fluciclatide uptake on autoradiography 
also corresponded to sites of immunohistochemical cellular 
staining for vascular endothelial cells and macrophages. This is 
in keeping with previous RGD- radiotracer studies and supports 
its role as a selective marker for angiogenic and inflammatory 
components of atherosclerotic activity.7 24 25 Due to the close 
relationship between intraplaque inflammation and angiogenesis 
however, we are unable to ascertain whether 18F- fluciclatide 
was binding preferentially to one or the other of these processes.
Dynamic in vivo imaging studies in 20 subjects confirmed 
irreversible 18F- fluciclatide binding to regions of aortic athero-
sclerosis over the selected acquisition time, and demonstrated 
that the optimum time for 18F- fluciclatide imaging in the aorta 
is between 40 and 70 min. This timeframe was used for subse-
quent static PET imaging across the cohort as a whole. Static 
in vivo imaging demonstrated reproducible quantification of 
18F- fluciclatide in aortic atheroma of all 46 patients, and this 
was correlated with the severity of aortic atherosclerotic burden, 
itself a manifestation of systemic atherosclerosis and a strong 
predictor of cardiovascular events.26 27 Indeed, associations were 
observed with the aortic calcium score, aortic wall thickness and 
overall plaque volume. In patients with clinically stable disease, 
aortic uptake of 18F- fluciclatide was increased in subjects with 
hypercholesterolaemia and those with ischaemic heart disease, 
with a trend towards higher uptake in patients with diabetes 
mellitus that did not meet statistical significance. Perhaps most 
importantly, 18F- fluciclatide uptake in aortic atheroma was 
increased in patients with unstable (recent MI) versus stable 
clinical disease. Interestingly, using 18F- fluorodeoxyglucose, 
we have previously demonstrated a similar pattern of increased 
metabolic activity in aortic atheroma among patients with recent 
MI.28 These data therefore lend support to the hypothesis that 
acute MI causes inflammation and instability in systemic athero-
sclerosis, as has been suggested in preclinical murine models.29 It 
also provides further validity to the concept that 18F- fluciclatide 
uptake can identify higher risk plaques. However, whether this 
increased disease activity truly represents a response to the infarct 
or rather the underlying trigger remains to be determined.
We acknowledge that there are limitations of our study that 
include potential partial volume artefacts, a limited histolog-
ical assessment and the use of surrogate measures for aortic 
histology. 18F- Fluciclatide imaging prior to carotid endarter-
ectomy would allow for a more direct comparison between in 
vivo imaging and histological assessment and consolidate our 
findings in line with previous publications.7 Furthermore, our 
exploratory assessment of aortic plaque volume may not take 
into account non- atheromatous intimal thickening in response 
to chronic hypertension. The dynamic imaging approach proved 
sensitive to patient movement during the prolonged acquisition 
period, limiting its utility in quantitative analysis, but this may 
ultimately be readdressed by novel motion tracking systems that 
allow for correction of cardiac and respiratory motion, enabling 
even greater definition of regional αvβ3 integrin expression.30 
Furthermore, given the limited number of patients studied using 
univariate analyses, we cannot exclude confounding of our 
results by other factors, nor that due to the multiple comparisons 
made, some tests may be statistically significant by chance alone. 
Nonetheless, we believe that the totality of our comprehensive 
evidence using multiple approaches and imaging modalities 
provides a robust and cogent argument to support our findings.
In conclusion, this is the largest study to date assessing αvβ3 
integrin expression in human atherosclerotic disease. We have 
demonstrated that 18F- fluciclatide uptake localises to regions 
of inflammation and angiogenesis, correlates with the plaque 
burden and is increased in patients with clinically unstable 
disease. Although further study is required, our data indicate 
that 18F- fluciclatide shows promise as a non- invasive marker of 
disease activity and instability in atherosclerosis.
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Key messages
What is already known on this subject?
 ► The alpha- V beta-3 (αvβ3) integrin receptor is a mediator 
of plaque angiogenesis and inflammation and has been 
targeted as a potential marker of atherosclerotic activity 
using positron emission tomography radiotracers.
 ► Studies of αvβ3 integrin- specific radiotracers in humans are 
lacking.
What might this study add?
 ► This is the largest study to date assessing αvβ3 integrin 
expression in human atherosclerosis.
 ► We have demonstrated that 18F- fluciclatide uptake localises 
to vascular inflammation and angiogenesis, correlates with 
plaque burden and is increased in patients with clinically 
unstable disease.
how might this impact on clinical practice?
 ► Non- invasive markers of atherosclerotic disease activity may 
identify vulnerable patients and provide incremental risk 
prediction to current anatomic imaging approaches.
 ► In this study, 18F- fluciclatide shows promise as a non- 
invasive marker of disease activity and instability in 
atherosclerosis.
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